From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
 | ETA cohort N=2885 | MTX cohort N=1517 |
---|---|---|
Female, n (%) | 1937 (67.1) | 1023 (67.4) |
Disease Duration, years, mean (SD) | 4.1 (3.7) | 2.1 (2.8) |
ANA positive, n (%) | 1388 (48.1) | 727 (47.9) |
HLA B 27 positive, n (%) | 685 (23.7) | 265 (17.5) |
AE, n; rate/100PY (95%CI) | 2531; 38.5 (37.1-40.1) | 1354; 34 (32.9-36.6) |
SAE, n; rate/100PY (95%CI) | 243; 3.7 (3.2-4.2) | 50; 1.3 (0.9-1.6) |
Serious infections, n; rate/100PY (95%CI) | 57; 2.0 (1.5-2.6) | 7; 0.5 (0.2-1.0) |
Baseline JADAS 10, mean (SD) | 15.2 (7.5) | 13.8 (7.1) |
Last observation JADAS 10, mean (SD) | 6.3 (7.2) | 5.3 (6.8) |